Michael H. Veeder

2.9k total citations · 1 hit paper
24 papers, 2.3k citations indexed

About

Michael H. Veeder is a scholar working on Oncology, Pathology and Forensic Medicine and Cancer Research. According to data from OpenAlex, Michael H. Veeder has authored 24 papers receiving a total of 2.3k indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Oncology, 6 papers in Pathology and Forensic Medicine and 6 papers in Cancer Research. Recurrent topics in Michael H. Veeder's work include Cancer Treatment and Pharmacology (8 papers), Breast Cancer Treatment Studies (5 papers) and Chronic Lymphocytic Leukemia Research (4 papers). Michael H. Veeder is often cited by papers focused on Cancer Treatment and Pharmacology (8 papers), Breast Cancer Treatment Studies (5 papers) and Chronic Lymphocytic Leukemia Research (4 papers). Michael H. Veeder collaborates with scholars based in United States, Canada and South Africa. Michael H. Veeder's co-authors include James A. Mailliard, Charles G. Moertel, Phyllis J. Goodman, Thomas R. Fleming, John S. Macdonald, Daniel G. Haller, John A. Laurie, Douglas C. Tormey, John H. Glick and James E. Krook and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Cancer.

In The Last Decade

Michael H. Veeder

24 papers receiving 2.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Levamisole and Fluorouracil for Adjuvant Therapy of Resected Colon Carcinoma

1990 1.7k citations Charles G. Moertel, Thomas R. Fleming et al. New England Journal of Medicine profile →

Peers

Countries citing papers authored by Michael H. Veeder

Since Specialization

Citations

This map shows the geographic impact of Michael H. Veeder's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael H. Veeder with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael H. Veeder more than expected).

Fields of papers citing papers by Michael H. Veeder

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael H. Veeder. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael H. Veeder. The network helps show where Michael H. Veeder may publish in the future.

Co-authorship network of co-authors of Michael H. Veeder

This figure shows the co-authorship network connecting the top 25 collaborators of Michael H. Veeder. A scholar is included among the top collaborators of Michael H. Veeder based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael H. Veeder. Michael H. Veeder is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	A Phase 1b/2 Study of the Bruton Tyrosine Kinase Inhibitor Ibrutinib and the PD-L1 Inhibitor Durvalumab in Patients with Pretreated Solid Tumors 2019 ·Oncology ·David S. Hong, Drew Rasco, Michael H. Veeder, Jason J. Luke, Jason C. Chandler, Ani Sarkis Balmanoukian, Thomas J. George, Pamela N. Münster, Jordan Berlin, Martin Gutierrez, Alain C. Mita, Heather A. Wakelee, Selda Samakoglu, (unknown), Isaiah W. Dimery, Thorsten Graef, Erkut Borazanci	66
2	Ibrutinib + durvalumab (MEDI4736) in patients (pts) with relapsed or refractory (R/R) pancreatic adenocarcinoma (PAC): A phase Ib/II multicenter study. 2016 ·Journal of Clinical Oncology ·Erkut Borazanci, David S. Hong, Martin Gutierrez, Drew Rasco, Tony R. Reid, Michael H. Veeder, (unknown), Jennifer Lin, Isaiah W. Dimery	8
3	Long‐term results of the treatment of patients with mantle cell lymphoma with cladribine (2‐CDA) alone (95‐80‐53) or 2‐CDA and rituximab (N0189) in the North Central Cancer Treatment Group 2008 ·Cancer ·David J. Inwards, Paul A. S. Fishkin, David W. Hillman, David W. Brown, Stephen M. Ansell, Paul J. Kurtin, Rafaël Fonseca, Roscoe F. Morton, Michael H. Veeder, Thomas E. Witzig	55
4	Hematologic and Cytogenetic Spontaneous Remission in Acute Monocytic Leukemia (FAB M5b) With Trisomy 8 2007 ·Journal of Clinical Oncology ·(unknown), Tinoy Kizhakekuttu, (unknown), Michael H. Veeder	10
5	Phase II Study of Gemcitabine Plus Cisplatin in Patients With Metastatic Breast Cancer 2005 ·American Journal of Clinical Oncology ·Patrick A. Burch, James A. Mailliard, David W. Hillman, Edith A. Perez, James E. Krook, Kendrith M. Rowland, Michael H. Veeder, Michael W. Cannon, James N. Ingle	28
6	A Phase II Trial of Docetaxel and Carboplatin as First-Line Chemotherapy for Metastatic Breast Cancer: NCCTG Study N9932 2005 ·Oncology ·Edith A. Perez, Vera J. Suman, Tom R. Fitch, James A. Mailliard, James N. Ingle, John T. Cole, Michael H. Veeder, Patrick J. Flynn, Daniel J. Walsh, (unknown)	17
7	O-125 ECOG 2597: Phase III study of induction chemotherapy followed by standard thoracic radiotherapy (STD TRT) vs hyperfractionated accelerated radiotherapy (HART) for patients with unresectable stage III A & B non-small cell lung cancer 2003 ·Lung Cancer ·Chandra P. Belani, (unknown), David H. Johnson, Henry Wagner, (unknown), Michael H. Veeder, Minesh P. Mehta	20
8	A randomized trial of tamoxifen alone or combined with octreotide in the treatment of women with metastatic breast carcinoma 1999 ·Cancer ·James N. Ingle, Vera J. Suman, Carl G. Kardinal, James E. Krook, James A. Mailliard, Michael H. Veeder, Charles L. Loprinzi, Robert J. Dalton, (unknown), Cheryl A. Conover, Michaël Pollak	53
9	Phase III Clinical Trial of the Combination of Cisplatin, Dacarbazine, and Carmustine With or Without Tamoxifen in Patients With Advanced Malignant Melanoma 1999 ·Journal of Clinical Oncology ·Edward T. Creagan, Vera J. Suman, Robert J. Dalton, Henry C. Pitot, Harry J. Long, Michael H. Veeder, Allen M. Vukov, Kendrith M. Rowland, James E. Krook, John C. Michalak	58
10	A Phase II Study of High-Dose Cimetidine and the Combination 5-Fluorouracil, Interferon Alpha-2A, and Leucovorin in Advanced Renal Cell Adenocarcinoma 1998 ·American Journal of Clinical Oncology ·Edward T. Creagan, Michael H. Veeder, Vera J. Suman, Patrick A. Burch, William J. Maples, Paul Schaefer, Delano M. Pfeifle, Robert J. Dalton, Alan K. Hatfield, Michael A. Poon	3
11	Mitoxantrone dose augmentation utilizing filgrastim support in combination with fixed-dose 5-fluorouracil and leucovorin in women with metastatic breast cancer 1997 ·Breast Cancer Research and Treatment ·James N. Ingle, Carl G. Kardinal, Vera J. Suman, Michael H. Veeder, Paul Schaefer, (unknown), James A. Mailliard	2
12	A Prospective Study of Pulmonary Function in Patients Receiving Mitomycin 1996 ·CHEST Journal ·Mário Augusto Ferrari de Castro, Michael H. Veeder, James A. Mailliard, Henry D. Tazelaar, James R. Jett	26
13	Transdermal Clonidine for Ameliorating Tamoxifen-Induced Hot Flashes 1996 ·Journal of Clinical Oncology ·Richard M. Goldberg, Charles L. Loprinzi, Judith R. OʼFallon, Michael H. Veeder, Angela W. Miser, James A. Mailliard, John C. Michalak, Ann Marie Dose, (unknown), Nora Burnham	5
14	Phase II Trial of Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Advanced/Recurrent Endometrial Carcinoma 1995 ·Gynecologic Oncology ·Harry J. Long, Robert M. Langdon, S. Stephen, Michael H. Veeder, Delano M. Pfeifle, James E. Krook, Larry P. Ebbert, Loren K. Tschetter, (unknown)	10
15	A phase III evaluation of a somatostatin analogue (octreotide) in the treatment of patients with asymptomatic advanced colon carcinoma 1995 ·Cancer ·(unknown), Charles G. Moertel, H. Samuel Wieand, James E. Krook, Allan J. Schutt, Michael H. Veeder, James A. Mailliard, Robert J. Dalton	32
16	Inhibition of 5 - fluorouracil-induced ocular irritation by ocular ice packs 1994 ·Cancer ·Charles L. Loprinzi, Donald B. Wender, Michael H. Veeder, Judith R. OʼFallon, Nancy L. Vaught, Ann Marie Dose, (unknown), (unknown), (unknown)	11
17	Phase II trial of edatrexate in small cell lung cancer 1994 ·Cancer ·Martin Wiesenfeld, James R. Jett, John Q. Su, (unknown), Carl G. Kardinal, James A. Mailliard, Michael H. Veeder, Roscoe F. Morton, John C. Michalak	10
18	A phase III trial of mitomycin C alone versus mitomycin C, vinblastine, and cisplatin for metastatic squamous cell lung carcinoma 1992 ·Cancer ·Michael H. Veeder, James R. Jett, John Q. Su, James A. Mailliard, John Foley, Robert J. Dalton, (unknown), Robert F. Marschke, Carl G. Kardinal, Andrew W. Maksymiuk, Larry P. Ebbert, Henry D. Tazelaar, (unknown)	26
19	Levamisole and Fluorouracil for Adjuvant Therapy of Resected Colon Carcinoma breakdown → 1990 ·New England Journal of Medicine ·Charles G. Moertel, Thomas R. Fleming, John S. Macdonald, Daniel G. Haller, John A. Laurie, Phyllis J. Goodman, (unknown), (unknown), Douglas C. Tormey, John H. Glick, Michael H. Veeder, James A. Mailliard	1722
20	Steroid‐responsive pure red cell aplasia associated with natural killer cell lymphocytosis 1989 ·American Journal of Hematology ·Ayalew Tefferi, Kevin Windebank, Michael H. Veeder, Joseph M. Kiely	6

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact